| abstract |
Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition (eg, a pharmaceutical composition), and in other embodiments, the peptide combination is provided as a kit. In yet another embodiment, the peptide combination is provided as a bond (eg, fusion peptide, heterodimer). In certain embodiments, the GIP agonist peptide is an analog of natural human glucagon. In certain embodiments, the glucagon antagonist peptide is an analog of natural human glucagon. In some embodiments, the GIP agonist peptide is covalently linked to the glucagon antagonist peptide via a linker. Further provided is a method of treating, for example, a metabolic disorder disease (diabetes, obesity, etc.) comprising administering the peptide composition described herein. [Selection figure] None |